Eric Tetzlaff
Physician Assistant, Assistant Professor
Make your next move.
Prepare your application
Review drafts before you send them.
Explore related searches
About
Eric Tetzlaff is an Assistant Professor at Fox Chase Cancer Center in the United States. His research primarily focuses on the well-being of healthcare professionals, particularly in the field of oncology. One of his recent articles examines the changes in burnout among oncology physician assistants between 2015 and 2019.
Articles (6)
PURPOSE Recent data suggest that the rate of burnout among oncologists has risen over time. In addition to the negative effect of burnout on individuals, widespread burnout may prevent the oncology workforce from meeting patient care needs. METHODS ASCO surveyed US-based oncologists in patient care roles about their professional well-being and satisfaction and the effect of both on their career plans. Burnout was assessed using measures of emotional exhaustion and depersonalization from the Maslach Burnout Inventory Human Services Survey. Data from the 2023 survey were compared with data from Shanafelt et al (JCO, 2014) collected about oncologist burnout/well-being in 2013. RESULTS In all, 328 responses to the 2023 survey were analyzed. Burnout was significantly higher compared with 2013, 45% in 2013 versus 59% in 2023 ( P < .01). In 2023, <25% of oncologists reported feeling satisfied with their work-life integration, compared with nearly 35% in 2013 ( P < .01). Burnout was significantly associated with being a caregiver in one’s personal life, being under age 50 years, and working more than 60 hours per week (all P < .05). Over 20% of respondents reported that it was likely or definite that they would reduce their clinical hours in the next 12 months. Additional practice/administrative support and reducing work hours were identified as potential solutions to improve job satisfaction. CONCLUSION Oncologists in 2023 are experiencing higher rates of burnout compared with a decade ago. System-based interventions to reduce burnout are necessary to maintaining an adequate workforce to provide care for current and future patients with cancer.
Year:
2025
Purpose: Dedifferentiated liposarcoma (DDL) and leiomyosarcoma (LMS) are two common subtypes of soft-tissue sarcoma, a rare group of diseases for which new treatments are needed. Chemotherapy remains the standard option for advanced disease. Targeting cyclin-dependent kinase 4 and 6 (CDK4/6) in DDL and mTOR in LMS is of biologic interest. When combined, the CDK4 inhibitor ribociclib and the mTOR inhibitor everolimus have shown synergistic growth inhibition in multiple tumor models, suggesting that this combination could be beneficial in patients. Patients and Methods: This was a single arm, open label, multicenter phase II study of the combination of ribociclib and everolimus. Patients were enrolled into one of two cohorts: DDL or LMS with intact Rb. The primary endpoint was progression-free rate (PFR) at 16 weeks. Secondary endpoints included progression-free survival (PFS) and overall survival, safety and biomarker analyses. Results: In the DDL cohort, 33.3% [95% confidence interval (CI), 15.6%–55.3%] of patients were progression-free at 16 weeks. Median PFS in this cohort was 15.4 weeks (95% CI, 8–36 weeks) with 2 partial responses. In the LMS cohort the PFR at 16 weeks was 29.2% (95% CI, 12.6%–51.1%). Median PFS in this cohort was 15.7 weeks (95% CI, 7.7–NA). Most common toxicities included fatigue (66.7%), anorexia (43.8%), and hyperglycemia (43.8%). Concordance between Rb testing methodologies was poor. Conclusions: The combination of ribociclib and everolimus demonstrates activity in DDL with prolonged stable disease (≥16 weeks) meeting the primary endpoint. Notably partial responses were observed. The primary endpoint was not reached in the LMS cohort. The combination was well tolerated with expected side effects.
Year:
2024
Purpose: Dedifferentiated liposarcoma (DDL) and leiomyosarcoma (LMS) are two common subtypes of soft-tissue sarcoma, a rare group of diseases for which new treatments are needed. Chemotherapy remains the standard option for advanced disease. Targeting cyclin-dependent kinase 4 and 6 (CDK4/6) in DDL and mTOR in LMS is of biologic interest. When combined, the CDK4 inhibitor ribociclib and the mTOR inhibitor everolimus have shown synergistic growth inhibition in multiple tumor models, suggesting that this combination could be beneficial in patients. Patients and Methods: This was a single arm, open label, multicenter phase II study of the combination of ribociclib and everolimus. Patients were enrolled into one of two cohorts: DDL or LMS with intact Rb. The primary endpoint was progression-free rate (PFR) at 16 weeks. Secondary endpoints included progression-free survival (PFS) and overall survival, safety and biomarker analyses. Results: In the DDL cohort, 33.3% [95% confidence interval (CI), 15.6%–55.3%] of patients were progression-free at 16 weeks. Median PFS in this cohort was 15.4 weeks (95% CI, 8–36 weeks) with 2 partial responses. In the LMS cohort the PFR at 16 weeks was 29.2% (95% CI, 12.6%–51.1%). Median PFS in this cohort was 15.7 weeks (95% CI, 7.7–NA). Most common toxicities included fatigue (66.7%), anorexia (43.8%), and hyperglycemia (43.8%). Concordance between Rb testing methodologies was poor. Conclusions: The combination of ribociclib and everolimus demonstrates activity in DDL with prolonged stable disease (≥16 weeks) meeting the primary endpoint. Notably partial responses were observed. The primary endpoint was not reached in the LMS cohort. The combination was well tolerated with expected side effects.
Year:
2024
Supplementary Figure S2: Heatmap and hierarchical clustering of significantly expressed genes between responders and non-responders in archival LMS samples. Heatmap and hierarchical clustering is based on the expression levels of the 96 genes which are differentially expressed. The cutoffs used are false discovery rate (FDR) =2. Each column represents a sample and each row represents a gene. The log2 relative gene expression scale is depicted on the right.
Year:
2024
Supplementary Figure S2: Heatmap and hierarchical clustering of significantly expressed genes between responders and non-responders in archival LMS samples. Heatmap and hierarchical clustering is based on the expression levels of the 96 genes which are differentially expressed. The cutoffs used are false discovery rate (FDR) =2. Each column represents a sample and each row represents a gene. The log2 relative gene expression scale is depicted on the right.
Year:
2024
Year:
2022
Collaborators (7)
Suzanne George
Harvard University
Judith Paice
Northwestern University Feinberg School of Medicine
Lori Rink
Associate Professor
Fox Chase Cancer Center
Margaret von Mehren
Professor
Fox Chase Cancer Center
Eric Winer
Director
Yale University
Edwin Choy
Associate Professor
Harvard Medical School
Elizabeth Handorf
Associate Professor
Rutgers, The State Univ. of NJ
Make your next move.
Prepare your application
Review drafts before you send them.